BiotechTube
AdaptVac

AdaptVac

Copenhagen, Denmark· Est.
adaptvac.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

AdaptVac is a clinical-stage vaccine developer with a validated, proprietary cVLP display platform. The company has advanced its platform through a Phase 3 COVID-19 vaccine (ABNCoV2) and has a pipeline including a HER2+ breast cancer vaccine in Phase 1 and a Nipah virus vaccine in pre-clinical development. With strong academic roots from the University of Copenhagen and significant non-dilutive funding, AdaptVac is positioned to create durable vaccines for both commercial and equitable access markets. Its business model is primarily out-licensing of vaccine candidates developed on its platform.

OncologyInfectious DiseasesImmunological Disorders

Technology Platform

Proprietary capsid Virus-Like Particle (cVLP) display platform using a Tag/Catcher (MoonCatcher) system for stable antigen conjugation. Based on the self-assembling Bacteriophage AP205 capsid protein produced in E. coli, designed to elicit strong and durable immune responses.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

The validated cVLP platform offers a rapid, modular path to develop durable vaccines for high-value commercial targets in oncology and infectious diseases, as well as for priority pathogens in global health.
Strong non-dilutive funding (€142M) provides a lengthy runway to advance the pipeline and seek strategic partnerships.
The demonstrated durability of immune response positions the platform favorably in markets dominated by vaccines requiring frequent boosting.

Risk Factors

Intense competition from established vaccine platforms (mRNA, recombinant proteins) requires demonstrating clear competitive advantages in efficacy, durability, or cost.
Clinical development risk remains high, particularly for the therapeutic cancer vaccine.
The company's reliance on out-licensing and partnerships introduces dependency on external execution and decision-making.

Competitive Landscape

AdaptVac competes in the vaccine platform space against major pharmaceutical companies with established technologies (e.g., GSK's adjuvant systems, Sanofi's recombinant proteins) and dominant new platforms like mRNA (Moderna, Pfizer/BioNTech). Its differentiation lies in the potential for longer-lasting immunity from a single dose and a potentially cheaper, scalable manufacturing process using E. coli. It also competes with other VLP-based companies but differentiates with its proprietary Tag/Catcher conjugation system.

More companies in Immunotherapy / Immuno-Oncology →More companies in Denmark →